Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14).

MLA

Furqan, Muhammad, et al. “Real-World Assessment of Treatment Effectiveness in Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) with MET Exon 14 Skipping (METex14).” Journal of Clinical Oncology, vol. 41, June 2023, p. e21112. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.e21112.

APA

Furqan, M., Karanth, S., Goyal, R. K., Shih, Y.-H., Cai, B., Rombi, J., Davis, K. L., Caro, N., & Saliba, T. R. (2023). Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Journal of Clinical Oncology, 41, e21112. https://doi.org/10.1200/JCO.2023.41.16_suppl.e21112

Chicago

Furqan, Muhammad, Siddharth Karanth, Ravi K. Goyal, Yu-Hsuan Shih, Beilei Cai, Julien Rombi, Keith L. Davis, Nydia Caro, and Teddy Rassem Saliba. 2023. “Real-World Assessment of Treatment Effectiveness in Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) with MET Exon 14 Skipping (METex14).” Journal of Clinical Oncology 41 (June): e21112. doi:10.1200/JCO.2023.41.16_suppl.e21112.